Pharsight

Nymalize is owned by Azurity.

Nymalize contains Nimodipine.

Nymalize has a total of 7 drug patents out of which 0 drug patents have expired.

Nymalize was authorised for market use on 10 May, 2013.

Nymalize is available in solution;oral dosage forms.

Nymalize can be used as a method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms.

The generics of Nymalize are possible to be released after 16 April, 2038.

^new

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070581	AZURITY	Dispenser for medicaments and method and apparatus for making same	Jun, 2023 (14 days from now)
US8517997	AZURITY	Dispenser for medicaments and method and apparatus for making same	May, 2024 (11 months from now)
US10576070	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)
US11207306	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)
US10342787	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)
US11413277	AZURITY	Non-aqueous liquid nimodipine compositions	Apr, 2038 (14 years from now)
US11517563	AZURITY	NA	Apr, 2038 (14 years from now)

Drugs and Companies using NIMODIPINE ingredient

Market Authorisation Date: 10 May, 2013

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry a...

Dosage: SOLUTION;ORAL